Development of in vitro and in vivo tools to evaluate the antiangiogenic potential of melatonin to neutralize the angiogenic effects of VEGF and breast cancer cells: CAM assay and 3D endothelial cell spheroids
Melatonin is a molecule with different antitumor actions in breast cancer and has been described as an inhibitor of vascular endothelial growth factor (VEGF). Despite the recognition of the key role exerted by VEGF in tumor angiogenesis, limitations arise when developing models to test new antiangio...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-01-01
|
| Series: | Biomedicine & Pharmacotherapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332222014305 |
| _version_ | 1811187726221836288 |
|---|---|
| author | Aurora Laborda-Illanes Lidia Sánchez-Alcoholado Daniel Castellano-Castillo Soukaina Boutriq Isaac Plaza-Andrades Lucía Aranega-Martín Jesús Peralta-Linero Emilio Alba Alicia González-González María Isabel Queipo-Ortuño |
| author_facet | Aurora Laborda-Illanes Lidia Sánchez-Alcoholado Daniel Castellano-Castillo Soukaina Boutriq Isaac Plaza-Andrades Lucía Aranega-Martín Jesús Peralta-Linero Emilio Alba Alicia González-González María Isabel Queipo-Ortuño |
| author_sort | Aurora Laborda-Illanes |
| collection | DOAJ |
| description | Melatonin is a molecule with different antitumor actions in breast cancer and has been described as an inhibitor of vascular endothelial growth factor (VEGF). Despite the recognition of the key role exerted by VEGF in tumor angiogenesis, limitations arise when developing models to test new antiangiogenic molecules. Thus, the aim of this study was to develop rapid, economic, high capacity and easy handling angiogenesis assays to test the antiangiogenic effects of melatonin and demonstrate its most effective dose to neutralize and interfere with the angiogenic sprouting effect induced by VEGF and MCF-7. To perform this, 3D endothelial cell (HUVEC) spheroids and a chicken embryo chorioallantoic membrane (CAM) assay were used. The results showed that VEGF and MCF-7 were able to stimulate the sprouting of the new vessels in 3D endothelial spheroids and the CAM assay, and that melatonin had an inhibitory effect on angiogenesis. Specifically, as the 1 mM pharmacological dose was the only effective dose able to inhibit the formation of ramifications around the alginate in the CAM assay model, this inhibition was shown to occur in a dose-dependent manner. Taken together, these techniques represent novel tools for the development of antiangiogenic molecules such as melatonin, with possible implications for the therapy of breast cancer. |
| first_indexed | 2024-04-11T14:08:20Z |
| format | Article |
| id | doaj.art-9ec277ca0d724e5bbd14f713ad064c34 |
| institution | Directory Open Access Journal |
| issn | 0753-3322 |
| language | English |
| last_indexed | 2024-04-11T14:08:20Z |
| publishDate | 2023-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biomedicine & Pharmacotherapy |
| spelling | doaj.art-9ec277ca0d724e5bbd14f713ad064c342022-12-22T04:19:49ZengElsevierBiomedicine & Pharmacotherapy0753-33222023-01-01157114041Development of in vitro and in vivo tools to evaluate the antiangiogenic potential of melatonin to neutralize the angiogenic effects of VEGF and breast cancer cells: CAM assay and 3D endothelial cell spheroidsAurora Laborda-Illanes0Lidia Sánchez-Alcoholado1Daniel Castellano-Castillo2Soukaina Boutriq3Isaac Plaza-Andrades4Lucía Aranega-Martín5Jesús Peralta-Linero6Emilio Alba7Alicia González-González8María Isabel Queipo-Ortuño9Intercenter Medical Oncology Clinical Management Unit, Regional and Virgen de la Victoria University Hospitals, Málaga Biomedical Research Institute (IBIMA)-CIMES-UMA, 29010 Málaga, SpainIntercenter Medical Oncology Clinical Management Unit, Regional and Virgen de la Victoria University Hospitals, Málaga Biomedical Research Institute (IBIMA)-CIMES-UMA, 29010 Málaga, SpainIntercenter Medical Oncology Clinical Management Unit, Regional and Virgen de la Victoria University Hospitals, Málaga Biomedical Research Institute (IBIMA)-CIMES-UMA, 29010 Málaga, SpainIntercenter Medical Oncology Clinical Management Unit, Regional and Virgen de la Victoria University Hospitals, Málaga Biomedical Research Institute (IBIMA)-CIMES-UMA, 29010 Málaga, SpainIntercenter Medical Oncology Clinical Management Unit, Regional and Virgen de la Victoria University Hospitals, Málaga Biomedical Research Institute (IBIMA)-CIMES-UMA, 29010 Málaga, SpainIntercenter Medical Oncology Clinical Management Unit, Regional and Virgen de la Victoria University Hospitals, Málaga Biomedical Research Institute (IBIMA)-CIMES-UMA, 29010 Málaga, SpainIntercenter Medical Oncology Clinical Management Unit, Regional and Virgen de la Victoria University Hospitals, Málaga Biomedical Research Institute (IBIMA)-CIMES-UMA, 29010 Málaga, SpainIntercenter Medical Oncology Clinical Management Unit, Regional and Virgen de la Victoria University Hospitals, Málaga Biomedical Research Institute (IBIMA)-CIMES-UMA, 29010 Málaga, Spain; Department of Medicine and Pediatrics. Faculty of Medicine, University of Malaga, 29071 Malaga, SpainIntercenter Medical Oncology Clinical Management Unit, Regional and Virgen de la Victoria University Hospitals, Málaga Biomedical Research Institute (IBIMA)-CIMES-UMA, 29010 Málaga, Spain; Department of Medicine and Pediatrics. Faculty of Medicine, University of Malaga, 29071 Malaga, Spain; Department of Physiology and Pharmacology. Faculty of Medicine, University of Cantabria, and Valdecilla Health Research Institute (IDIVAL), 39011 Santander, Spain; Corresponding author at: Intercenter Medical Oncology Clinical Management Unit, Regional and Virgen de la Victoria University Hospitals, Málaga Biomedical Research Institute (IBIMA)-CIMES-UMA, 29010 Málaga, Spain.Intercenter Medical Oncology Clinical Management Unit, Regional and Virgen de la Victoria University Hospitals, Málaga Biomedical Research Institute (IBIMA)-CIMES-UMA, 29010 Málaga, Spain; Department of Surgical Specialties, Biochemical and Immunology. Faculty of Medicine, University of Málaga, 29071 Malaga, SpainMelatonin is a molecule with different antitumor actions in breast cancer and has been described as an inhibitor of vascular endothelial growth factor (VEGF). Despite the recognition of the key role exerted by VEGF in tumor angiogenesis, limitations arise when developing models to test new antiangiogenic molecules. Thus, the aim of this study was to develop rapid, economic, high capacity and easy handling angiogenesis assays to test the antiangiogenic effects of melatonin and demonstrate its most effective dose to neutralize and interfere with the angiogenic sprouting effect induced by VEGF and MCF-7. To perform this, 3D endothelial cell (HUVEC) spheroids and a chicken embryo chorioallantoic membrane (CAM) assay were used. The results showed that VEGF and MCF-7 were able to stimulate the sprouting of the new vessels in 3D endothelial spheroids and the CAM assay, and that melatonin had an inhibitory effect on angiogenesis. Specifically, as the 1 mM pharmacological dose was the only effective dose able to inhibit the formation of ramifications around the alginate in the CAM assay model, this inhibition was shown to occur in a dose-dependent manner. Taken together, these techniques represent novel tools for the development of antiangiogenic molecules such as melatonin, with possible implications for the therapy of breast cancer.http://www.sciencedirect.com/science/article/pii/S0753332222014305MelatoninVEGFEndothelial cellsHUVECMCF-7Spheroids |
| spellingShingle | Aurora Laborda-Illanes Lidia Sánchez-Alcoholado Daniel Castellano-Castillo Soukaina Boutriq Isaac Plaza-Andrades Lucía Aranega-Martín Jesús Peralta-Linero Emilio Alba Alicia González-González María Isabel Queipo-Ortuño Development of in vitro and in vivo tools to evaluate the antiangiogenic potential of melatonin to neutralize the angiogenic effects of VEGF and breast cancer cells: CAM assay and 3D endothelial cell spheroids Biomedicine & Pharmacotherapy Melatonin VEGF Endothelial cells HUVEC MCF-7 Spheroids |
| title | Development of in vitro and in vivo tools to evaluate the antiangiogenic potential of melatonin to neutralize the angiogenic effects of VEGF and breast cancer cells: CAM assay and 3D endothelial cell spheroids |
| title_full | Development of in vitro and in vivo tools to evaluate the antiangiogenic potential of melatonin to neutralize the angiogenic effects of VEGF and breast cancer cells: CAM assay and 3D endothelial cell spheroids |
| title_fullStr | Development of in vitro and in vivo tools to evaluate the antiangiogenic potential of melatonin to neutralize the angiogenic effects of VEGF and breast cancer cells: CAM assay and 3D endothelial cell spheroids |
| title_full_unstemmed | Development of in vitro and in vivo tools to evaluate the antiangiogenic potential of melatonin to neutralize the angiogenic effects of VEGF and breast cancer cells: CAM assay and 3D endothelial cell spheroids |
| title_short | Development of in vitro and in vivo tools to evaluate the antiangiogenic potential of melatonin to neutralize the angiogenic effects of VEGF and breast cancer cells: CAM assay and 3D endothelial cell spheroids |
| title_sort | development of in vitro and in vivo tools to evaluate the antiangiogenic potential of melatonin to neutralize the angiogenic effects of vegf and breast cancer cells cam assay and 3d endothelial cell spheroids |
| topic | Melatonin VEGF Endothelial cells HUVEC MCF-7 Spheroids |
| url | http://www.sciencedirect.com/science/article/pii/S0753332222014305 |
| work_keys_str_mv | AT auroralabordaillanes developmentofinvitroandinvivotoolstoevaluatetheantiangiogenicpotentialofmelatonintoneutralizetheangiogeniceffectsofvegfandbreastcancercellscamassayand3dendothelialcellspheroids AT lidiasanchezalcoholado developmentofinvitroandinvivotoolstoevaluatetheantiangiogenicpotentialofmelatonintoneutralizetheangiogeniceffectsofvegfandbreastcancercellscamassayand3dendothelialcellspheroids AT danielcastellanocastillo developmentofinvitroandinvivotoolstoevaluatetheantiangiogenicpotentialofmelatonintoneutralizetheangiogeniceffectsofvegfandbreastcancercellscamassayand3dendothelialcellspheroids AT soukainaboutriq developmentofinvitroandinvivotoolstoevaluatetheantiangiogenicpotentialofmelatonintoneutralizetheangiogeniceffectsofvegfandbreastcancercellscamassayand3dendothelialcellspheroids AT isaacplazaandrades developmentofinvitroandinvivotoolstoevaluatetheantiangiogenicpotentialofmelatonintoneutralizetheangiogeniceffectsofvegfandbreastcancercellscamassayand3dendothelialcellspheroids AT luciaaranegamartin developmentofinvitroandinvivotoolstoevaluatetheantiangiogenicpotentialofmelatonintoneutralizetheangiogeniceffectsofvegfandbreastcancercellscamassayand3dendothelialcellspheroids AT jesusperaltalinero developmentofinvitroandinvivotoolstoevaluatetheantiangiogenicpotentialofmelatonintoneutralizetheangiogeniceffectsofvegfandbreastcancercellscamassayand3dendothelialcellspheroids AT emilioalba developmentofinvitroandinvivotoolstoevaluatetheantiangiogenicpotentialofmelatonintoneutralizetheangiogeniceffectsofvegfandbreastcancercellscamassayand3dendothelialcellspheroids AT aliciagonzalezgonzalez developmentofinvitroandinvivotoolstoevaluatetheantiangiogenicpotentialofmelatonintoneutralizetheangiogeniceffectsofvegfandbreastcancercellscamassayand3dendothelialcellspheroids AT mariaisabelqueipoortuno developmentofinvitroandinvivotoolstoevaluatetheantiangiogenicpotentialofmelatonintoneutralizetheangiogeniceffectsofvegfandbreastcancercellscamassayand3dendothelialcellspheroids |